These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2886354)

  • 41. Apomorphine anorexia: the role of dopamine receptors in the ventral forebrain.
    Towell A; Willner P; Muscat R
    Psychopharmacology (Berl); 1988; 96(1):135-41. PubMed ID: 2906442
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased grooming behaviour is induced by apomorphine in mice treated with discriminant benzamide derivatives.
    Vasse M; Protais P
    Eur J Pharmacol; 1988 Oct; 156(1):1-11. PubMed ID: 2905270
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dopamine autoreceptor and postsynaptic receptor blocking potency of neuroleptics.
    Kendler KS; Bracha HS; Davis KL
    Eur J Pharmacol; 1982 Apr; 79(3-4):217-23. PubMed ID: 6124428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat.
    Swerdlow NR; Keith VA; Braff DL; Geyer MA
    J Pharmacol Exp Ther; 1991 Feb; 256(2):530-6. PubMed ID: 1825226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The D-1 antagonist SCH 23390 stimulates while the D-1 agonist SKF 38393 fails to affect dopamine release in the dorsal caudate of freely moving rats.
    Imperato A; Mulas A; Di Chiara G
    Eur J Pharmacol; 1987 Oct; 142(1):177-81. PubMed ID: 2891544
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A10 dopamine neurons: role of autoreceptors in determining firing rate and sensitivity to dopamine agonists.
    White FJ; Wang RY
    Life Sci; 1984 Mar; 34(12):1161-70. PubMed ID: 6708722
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity.
    Rasmussen K; Stockton ME; Czachura JF; Howbert JJ
    Eur J Pharmacol; 1991 Dec; 209(1-2):135-8. PubMed ID: 1687681
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.
    Iorio LC; Barnett A; Leitz FH; Houser VP; Korduba CA
    J Pharmacol Exp Ther; 1983 Aug; 226(2):462-8. PubMed ID: 6135795
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Repeated administration of (-)sulpiride and SCH 23390 differentially up-regulate D-1 and D-2 dopamine receptor function in rat mesostriatal areas but not in cortical-limbic brain regions.
    Memo M; Pizzi M; Nisoli E; Missale C; Carruba MO; Spano P
    Eur J Pharmacol; 1987 Jun; 138(1):45-51. PubMed ID: 2887436
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons.
    Stockton ME; Rasmussen K
    Neuropsychopharmacology; 1996 Feb; 14(2):97-105. PubMed ID: 8822532
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Similarity of clozapine and SCH 23390 in reserpinized rats suggests a common mechanism of action.
    Chipkin RE; Latranyi MB
    Eur J Pharmacol; 1987 Apr; 136(3):371-5. PubMed ID: 2886345
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Electrophysiological effects of E-5842, a sigma1 receptor ligand and potential atypical antipsychotic, on A9 and A10 dopamine neurons.
    Sánchez-Arroyos R; Guitart X
    Eur J Pharmacol; 1999 Jul; 378(1):31-7. PubMed ID: 10478562
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons.
    Rasmussen K; Czachura JF; Stockton ME; Howbert JJ
    J Pharmacol Exp Ther; 1993 Jan; 264(1):480-8. PubMed ID: 8423546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of chronic SCH 23390 treatment on dopamine autoreceptor function in rat brain.
    Lappalainen J; Hietala J; Sjöholm B; Syvälahti E
    Eur J Pharmacol; 1990 Apr; 179(3):315-21. PubMed ID: 1973105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors.
    Niedzwiecki DM; Mailman RB; Cubeddu LX
    J Pharmacol Exp Ther; 1984 Mar; 228(3):636-9. PubMed ID: 6707914
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of non-dopamine cells in the ventral tegmental area by benzodiazepines: relationship to A10 dopamine cell activity.
    O'Brien DP; White FJ
    Eur J Pharmacol; 1987 Oct; 142(3):343-54. PubMed ID: 2892684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Morphine-induced activation of A10 dopamine neurons in the rat.
    Gysling K; Wang RY
    Brain Res; 1983 Oct; 277(1):119-27. PubMed ID: 6315137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-additivity of D2 receptor proliferation induced by dopamine denervation and chronic selective antagonist administration: evidence from quantitative autoradiography indicates a single mechanism of action.
    LaHoste GJ; Marshall JF
    Brain Res; 1989 Nov; 502(2):223-32. PubMed ID: 2531015
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens.
    Li Z; Ichikawa J; Meltzer HY
    Psychopharmacology (Berl); 2003 May; 167(3):315-23. PubMed ID: 12664192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of neuroleptic drugs on the inhibition of exploratory behaviour induced by a low dose of apomorphine: implications for the identity of dopamine receptors.
    Ståhle L; Ungerstedt U
    Pharmacol Biochem Behav; 1986 Aug; 25(2):473-80. PubMed ID: 2876441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.